Predicine is a biotechnology company based in Hayward, CA that specializes in advancing precision medicine through their next-generation liquid biopsy platform. Their proprietary GeneRADAR technology allows for simultaneous profiling of DNA and RNA from a tube of blood, providing accurate and in-depth insights into cancer biology. With a focus on molecular profiling and clinical trials, Predicine collaborates with leading biopharmaceutical companies to support biomarker-driven research and development in the field of oncology.
Through their innovative urine-based liquid biopsy, Predicine offers a fast, easy, and non-invasive method for cancer detection, particularly in genitourinary cancers. Their comprehensive molecular profiling assays and co-development services provide robust variant detection and powerful data analysis, enabling the acceleration of oncology drug development. With a commitment to advancing precision medicine, Predicine is at the forefront of revolutionizing cancer diagnostics and treatment through their cutting-edge technology and strategic collaborations.
Generated from the website